BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260322
DTEND;VALUE=DATE:20260326
DTSTAMP:20260312T111337Z
CREATED:20260122T141811Z
LAST-MODIFIED:20260312T111337Z
UID:36486-1774137600-1774483199@senzagen.com
SUMMARY:2026 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #1934\nSan Diego\, CA\, USA\nJoin our scientific sessions and poster presentations at this year’s SOT\, featuring the latest GARD® data and case studies generated in collaboration with industry leaders. \nMeet us at booth #1934 and discuss your specific testing needs with our scientific team – We help you design testing strategies tailored to your substances and regulatory goals: from “2 out of 3” defined approaches according to OECD 497\, to exploratory studies supporting product development. \n \nExhibitor-Hosted Session\nAdvancing NAMs for Skin and Respiratory Sensitization: UVCBs\, Natural Extracts and Medical Devices \nNew GARD® advances in respiratory sensitization\,  ISO 10993-10 compliance for medical devices\, quantitative potency assessment\, and difficult-to-test samples \nRoom 23A | Tue\, 24 March | 10:45 am-11:45 am\n \n1. Introduction to GARD® technology for skin and respiratory sensitization testing \n🎤Andy Forreryd\, PhD |  Scientific Liaison\, SenzaGen  \n2. Evaluating sensitization potential of medical devices in vitro using GARD®skin assay: a practical in vitro sensitization case study in medical device development \n🎤Yizhong Liu\, PhD\, DABT | Senior Scientist and Toxicologist\, Johnson & Johnson MedTech  \n3. GARD®air for the prediction of respiratory sensitization for substances of regulatory concern \n🎤Emily Reinke\, PhD\, DABT | Principal Toxicologist\, GDIT (contractor supporting NICEATM)  \n4. Respiratory sensitization hazard identification: navigating assay exploration for biocatalytic enzymes \n🎤Joshua Vaughan\, PhD\, DABT | Principal Scientist\, Merck  \nSpeaking in Symposium Sessions\nIn Vitro Testing for Skin Sensitization of Mixtures: Where Science Stands Today \nRoom 7B | Wed\, 25 March | 8:00 am-10:45 am \nChairs: The Honest Company\, Edgewell Personal Care | SenzaGen: Dr Tim Lindberg | SenzaGen: Dr Tim Lindberg \nHuman Health Risk Assessments of Biopesticides: Evaluating Safety for Agricultural Use \nBallroom 6F | Wed\, 25 March | 1:30 PM-4:15 PM \nChairs: Bayer Crop Science\, Corteva Agriscience | SenzaGen: Dr Andy Forreryd \nPosters\n🎫 K764 | #5200 | Case study: Fragrance formulations – Jointly with Coty \nImproving the safety profiles of fragrance formulations: modulating the skin sensitization potential to reduce or eliminate the risk of allergic skin reactions \n🎫 K762 | #5198 | Case study: 2o3 DA applied to UVCBs – Jointly with ExxonMobil \nApplying the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of UVCBs using the GARD®skin and EpiSensA assays \n🎫 K759 | #5195 | Case study: NESIL prediction for OTC drugs – Jointly with Haleon  \nPredicting NESIL using New Approach Methodologies: a case study on quantitative skin sensitization assessment of topical over-the-counter pharmaceutical candidates \n🎫B175 | #3072 | Medical Device ISO 10993-10 \nIn vitro sensitization assessment of medical device extracts: Prevalidation results of GARD®skin Medical Device for potential inclusion in ISO 10993-10 \n🎫G546 | #3403 | New alternative gene expression platform for GARD® \nRNA-seq can be used for gene expression quantification in the GARD®skin method for assessment of skin sensitizers
URL:https://senzagen.com/event/2026sot/
LOCATION:San Diego\, CA\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/2026-SOT-eventpage-banner-2.png
END:VEVENT
END:VCALENDAR